BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/14/2025 12:55:52 PM | Browse: 335 | Download: 778
Publication Name World Journal of Gastrointestinal Oncology
Manuscript ID 103337
Country China
ISSN 1948-5204 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Review
Article Title Importance of landscape exploration and progress in molecular therapies and precision medicine for pancreatic ductal adenocarcinoma
Manuscript Source Unsolicited Manuscript
All Author List Maher Hendi, Bin Zhang, Yi-Ping Mou and Xiu-Jun Cai
ORCID
Author(s) ORCID Number
Bin Zhang http://orcid.org/0000-0002-6888-811X
Xiu-Jun Cai http://orcid.org/0000-0002-8178-0760
Funding Agency and Grant Number
Corresponding Author Xiu-Jun Cai, Chief Physician, FACS, FRCS, MD, PhD, President, Professor, Department of General Surgery, Zhejiang University School of Medicine, Sir Run Run Shaw Hospital, No. 3 Qingchun Road, Hangzhou 310016, Zhejiang Province, China. srrs_cxj@zju.edu.cn
Key Words Pancreatic ductal adenocarcinoma; Molecular subtypes; Transcriptomic; Microenvironment; Precision medicine; Therapeutic targets; Immunotherapy
Core Tip Pancreatic ductal adenocarcinoma is the fourth leading cause of cancer death globally and is projected to be the second leading cause later. Kirsten rat sarcoma oncogene is a critical target for treatment regime evaluation in pancreatic ductal adenocarcinoma and proof of principle approaches have validated targeting in Kirsten rat sarcoma oncogene G12C. FOLFIRINOX and nab-paclitaxel gemcitabine are gold standard therapeutic in patients. The combinations were shown a survival benefit over previously standard gemcitabine monotherapy. Therapies targeting as well as immuno-therapies hold promise for the future but are currently not standard of care.
Publish Date 2025-07-14 12:55
Citation

Hendi M, Zhang B, Mou YP, Cai XJ. Importance of landscape exploration and progress in molecular therapies and precision medicine for pancreatic ductal adenocarcinoma. World J Gastrointest Oncol 2025; 17(7): 103337

URL https://www.wjgnet.com/1948-5204/full/v17/i7/103337.htm
DOI https://dx.doi.org/10.4251/wjgo.v17.i7.103337
Full Article (PDF) WJGO-17-103337-with-cover.pdf